

# Stuart L Goldberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5265604/publications.pdf>

Version: 2024-02-01

73  
papers

1,564  
citations

567281

15  
h-index

315739

38  
g-index

76  
all docs

76  
docs citations

76  
times ranked

2913  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data. <i>European Journal of Haematology</i> , 2021, 106, 82-89.	2.2	14
2	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. <i>JCI Insight</i> , 2021, 6, .	5.0	29
3	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	4.1	4
4	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. <i>Lancet Rheumatology</i> , The, 2020, 2, e603-e612.	3.9	228
5	Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. <i>Journal of Clinical Oncology</i> , 2020, 38, 1367-1368.	1.6	4
6	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	4.1	11
7	Differential impact of cognitive computing augmented by real world evidence on novice and expert oncologists. <i>Cancer Medicine</i> , 2019, 8, 6578-6584.	2.8	12
8	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 2384-2393.	1.3	11
9	Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 213-219.e4.	0.4	3
10	Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	20
11	Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , 2019, 94, 46-54.	4.1	32
12	Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma. <i>Blood</i> , 2019, 134, 3141-3141.	1.4	2
13	Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias. <i>Blood</i> , 2019, 134, 3812-3812.	1.4	13
14	Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients. <i>Blood</i> , 2019, 134, 4576-4576.	1.4	3
15	Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma. <i>Blood</i> , 2019, 134, 2193-2193.	1.4	0
16	Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC). <i>Blood</i> , 2019, 134, 4475-4475.	1.4	0
17	Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 3316-3316.	1.4	1
18	Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2019, 134, 2929-2929.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice. <i>Blood</i> , 2019, 134, 4151-4151.	1.4	0
20	Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 5510-5510.	1.4	1
21	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. <i>Leukemia and Lymphoma</i> , 2018, 59, 2135-2143.	1.3	5
22	Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 98-105.	0.4	8
23	Development of a Precise, Clinically Relevant, Digital Classification Schema for Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-10.	2.1	5
24	Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. <i>Blood</i> , 2018, 132, 598-607.	1.4	128
25	The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients. <i>Blood</i> , 2018, 132, 5600-5600.	1.4	0
26	Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey. <i>Blood</i> , 2018, 132, 5843-5843.	1.4	0
27	Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice. <i>Blood</i> , 2018, 132, 1730-1730.	1.4	0
28	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	10.7	402
29	First-line treatment selection and early monitoring patterns in chronic phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , 2017, 92, 1214-1223.	4.1	36
30	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. <i>Blood</i> , 2017, 130, 891-891.	1.4	6
31	Real-world economic value of a 21-gene assay in early-stage breast cancer. <i>American Journal of Managed Care</i> , 2017, 23, e416-e420.	1.1	4
32	Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 341-349.e1.	0.4	11
33	Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2016, 128, 2973-2973.	1.4	1
34	Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice. <i>Blood</i> , 2016, 128, 937-937.	1.4	2
35	Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7014-7014.	1.6	0
36	Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7061-7061.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Meta-Analysis of Randomized Controlled Trials. <i>Blood</i> , 2016, 128, 5596-5596.	1.4	0
38	Barriers to Physician Adherence to Evidence-Based Monitoring Guidelines in Chronic Myelogenous Leukemia. <i>Journal of Oncology Practice</i> , 2015, 11, e398-e404.	2.5	29
39	Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 711-714.	0.4	15
40	Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. <i>Blood</i> , 2015, 126, 321-321.	1.4	19
41	A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR. <i>Blood</i> , 2015, 126, 5168-5168.	1.4	2
42	Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. <i>Current Medical Research and Opinion</i> , 2014, 30, 1345-1352.	1.9	41
43	The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1211-1216.	2.0	47
44	Predictors of performing response monitoring in patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY).. <i>Journal of Clinical Oncology</i> , 2014, 32, 116-116.	1.6	4
45	Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. <i>Current Medical Research and Opinion</i> , 2013, 29, 1075-1082.	1.9	49
46	Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR4.5) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENEStnext Study Update. <i>Blood</i> , 2013, 122, 4015-4015.	1.4	1
47	Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.. <i>Blood</i> , 2009, 114, 2089-2089.	1.4	12
48	Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.. <i>Blood</i> , 2009, 114, 2206-2206.	1.4	1
49	Myelodysplastic Syndrome Patients Obtaining a Cytogenetic Response to Outpatient Decitabine Experience Improved Hematological Responses and Longer Survival: Additional Analyses From the ADOPT Trial.. <i>Blood</i> , 2009, 114, 3817-3817.	1.4	3
50	Combination Melphalan and Bortezomib Conditioning with Autologous Hematopoietic Stem Cell Support in Patients with Advanced Multiple Myeloma. A Phase I/II Study.. <i>Blood</i> , 2009, 114, 1214-1214.	1.4	1
51	Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2008, 112, 3051-3051.	1.4	5
52	Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Blood</i> , 2008, 112, 3651-3651.	1.4	6
53	A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to BCR-ABL Tyrosine Kinase Inhibitors. <i>Blood</i> , 2008, 112, 4254-4254.	1.4	7
54	A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results. <i>Blood</i> , 2008, 112, 5084-5084.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Clinical and Economic Consequences of Myelodysplastic Syndromes in the United States: An Analysis of the Medicare Database. <i>Blood</i> , 2008, 112, 636-636.	1.4	9
56	Guillain-Barre Syndrome Complicating Multiple Myeloma. <i>Blood</i> , 2008, 112, 5135-5135.	1.4	1
57	Outcome of Patients with Myeloproliferative Disorders Treated with Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 2797-2797.	1.4	0
58	Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CPCML).. <i>Blood</i> , 2008, 112, 2128-2128.	1.4	0
59	Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2007, 31, S16-S22.	0.8	16
60	A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.. <i>Blood</i> , 2007, 110, 2569-2569.	1.4	18
61	Cryopreservation of Peripheral Blood Stem Cells (PBSC) with Hydroxyethylstarch (HES) and Dimethylsulfoxide (DMSO) Results in Faster Granulocyte Recovery Than Using Dimethylsulfoxide Alone.. <i>Blood</i> , 2007, 110, 3287-3287.	1.4	0
62	DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma.. <i>Blood</i> , 2007, 110, 3284-3284.	1.4	0
63	Treatment of T Cell Large Granular Lymphocyte Leukemia with Reduced-Intensity Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 4931-4931.	1.4	2
64	Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2006, 108, 2657-2657.	1.4	2
65	5-Azacitidine Therapy in Elderly Patients with Acute Myelogenous Leukemia Yields Similar Survival Compared to 3+7 Induction Chemotherapy with Less Transfusional Support, Bacteremias, and Hospital Days.. <i>Blood</i> , 2006, 108, 4569-4569.	1.4	0
66	Long-Term Survival of Patients with Myelofibrosis Treated with Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 2704-2704.	1.4	0
67	Interim Analysis of a Multicenter Trial of High Dose (HD) Imatinib in Newly Diagnosed Early Chronic Phase (CP) Patients (pt) with Chronic Myeloid Leukemia (CML).. <i>Blood</i> , 2005, 106, 1085-1085.	1.4	2
68	Comprehensive Immune Reconstitution without Development of Graft Versus Host Disease (GvHD) Using Limited T-Cell Add Back at the Time of Unrelated Multi-Antigen Mismatched Pan-T-Cell Depleted Transplant.. <i>Blood</i> , 2005, 106, 5383-5383.	1.4	0
69	Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies. <i>Supportive Care in Cancer</i> , 2004, 12, 526-30.	2.2	24
70	Risk Adapted Dose Intensive DICEP Salvage Chemotherapy Prior to Autologous Stem Cell Transplantation Yields Successful Outcomes in Chemotherapy Refractory Lymphoma.. <i>Blood</i> , 2004, 104, 898-898.	1.4	1
71	Autologous Peripheral Blood Stem Cell Transplant for Relapsed or Refractory T-Cell Non-Hodgkinâ€™s Lymphoma Results in Inferior Long Term Survival when Compared to Relapsed or Refractory B-Cell Non-Hodgkinâ€™s Lymphomas.. <i>Blood</i> , 2004, 104, 5241-5241.	1.4	0
72	A Myeloablative Conditioning Regimen Is Required to Produce Durable Engraftment and Immune Reconstitution in Related and Unrelated Multi-Antigen HLA Mismatched Pan-T-Cell Depleted Limited T-Cell Add-Back Transplants.. <i>Blood</i> , 2004, 104, 5185-5185.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. <i>Blood</i> , 2002, 99, 1486-1488.	1.4	180